Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Mar 23:15:17562848221085889.
doi: 10.1177/17562848221085889. eCollection 2022.

Evidence-based efficacy of methotrexate in adult Crohn's disease in different intestinal and extraintestinal indications

Andrea Cassinotti  1 , Alberto Batticciotto  2 , Marco Parravicini  3 , Maurizio Lombardo  4 , Paolo Radice  5 , Claudio Camillo Cortelezzi  3 , Simone Segato  3 , Federico Zanzi  3 , Antonella Cappelli  2 , Sergio Segato  3
Affiliations
Review

Evidence-based efficacy of methotrexate in adult Crohn's disease in different intestinal and extraintestinal indications

Andrea Cassinotti et al. Therap Adv Gastroenterol. .

Abstract

Introduction: Methotrexate (MTX) is included in the therapeutic armamentarium of Crohn's disease (CD), although its positioning is currently uncertain in an era in which many effective biological drugs are available. No systematic reviews or meta-analysis have stratified the clinical outcomes of MTX according to the specific clinical scenarios of its use.

Methods: Medline, PubMed and Scopus were used to extract eligible studies, from database inception to May 2021. A total of 163 studies were included. A systematic review was performed by stratifying the outcomes of MTX according to formulation, clinical indication and criteria of efficacy.

Results: The use of MTX is supported by randomized clinical trials only in steroid-dependent CD, with similar outcomes to thiopurines. The use of MTX in patients with steroid-refractoriness, failure of thiopurines or in combination with biologics is not supported by high levels of evidence. Combination therapy with biologics can optimize the immunogenic profile of the biological drug, but the impact on long-term clinical outcomes is described only in small series with anti-TNFα. Other off-label uses, such as fistulizing disease, mucosal healing, postoperative prevention and extraintestinal manifestations, are described in small uncontrolled series. The best performance in most indications was shown by parenteral MTX, favouring higher doses (25 mg/week) in the induction phase.

Discussion: Evidence from high-quality studies in favour of MTX is scarce and limited to the steroid-dependent disease, in which other drugs are the leading players today. Many limitations on study design have been found, such as the prevalence of retrospective underpowered studies and the lack of stratification of outcomes according to specific types of patients and formulations of MTX.

Conclusion: MTX is a valid option as steroid-sparing agent in steroid-dependent CD. Numerous other clinical scenarios require well-designed clinical studies in terms of patient profile, drug formulation and dosage, and criteria of efficacy.

Keywords: Crohn’s disease; extraintestinal manifestations; methotrexate.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement: The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Figures

Figure 1.
Figure 1.
PRISMA flow diagram of study screening and selection.
Figure 2.
Figure 2.
Positioning MTX use according to intestinal and extraintestinal indications in CD.
See this image and copyright information in PMC

References

    1. Kozarek RA, Patterson DJ, Gelfand MD, et al.. Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease. Ann Intern Med 1989; 110: 353–356. - PubMed
    1. Torres J, Bonovas S, Doherty G, et al.. ECCO guidelines on therapeutics in Crohn’s disease: medical treatment. J Crohns Colitis 2020; 14: 4–22. - PubMed
    1. Panaccione R, Steinhart H, Bressler B, et al.. Canadian association of gastroenterology clinical practice guideline for the management of luminal Crohn’s disease. J Can Ass Gastroenterol 2019; 2: e1–e34. - PMC - PubMed
    1. Terdiman JP, Gruss CB, Heidelbaugh JJ, et al.. American Gastroenterological Association Institute Guideline on the use of thiopurines, methotrexate and, anti-TNF-α biologic Drugs for the induction and maintenance of remission inflammatory Crohn’s disease. Gastroenterology 2013; 145: 1459–1463. - PubMed
    1. Lamb CA, Kennedy NA, Raine T, et al.. British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults. Gut 2019; 68: s1–s106. - PMC - PubMed

LinkOut - more resources